New antibody drug targets Cancer-Related fluid in the lungs
NCT ID NCT05543330
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tests a new drug called M701, a bispecific antibody, in people with advanced non-small cell lung cancer that has caused fluid buildup in the chest (malignant pleural effusion). The drug is given directly into the chest cavity to target cancer cells and help control the fluid. The trial will enroll about 96 participants to check safety, side effects, and how well the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- M701 (a bispecific antibody targeting EpCAM and CD3)
- What this could lead to
- If successful, this could lead to a new treatment option to control fluid buildup in the chest caused by advanced lung cancer, improving breathing and quality of life.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the treatment may not work or could cause significant side effects. The results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL EFFUSIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
RECRUITINGHangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New injection targets cancer fluid in lungs and belly
- New drug cocktail shows promise for Hard-to-Treat lung cancer
- New hope for drug-resistant lung cancer: combo therapy enters trial
- New scan may reveal who will benefit from immunotherapy
- Can extra immunotherapy stall advanced lung cancer?
- Blood test may predict lung cancer drug success